JP2005531488A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005531488A5 JP2005531488A5 JP2003533940A JP2003533940A JP2005531488A5 JP 2005531488 A5 JP2005531488 A5 JP 2005531488A5 JP 2003533940 A JP2003533940 A JP 2003533940A JP 2003533940 A JP2003533940 A JP 2003533940A JP 2005531488 A5 JP2005531488 A5 JP 2005531488A5
- Authority
- JP
- Japan
- Prior art keywords
- alkoxy
- alkyl
- compound
- pharmaceutically acceptable
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 description 4
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 3
- -1 1-oxo-thia morpholino Chemical group 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32788001P | 2001-10-09 | 2001-10-09 | |
| PCT/US2002/032195 WO2003030908A2 (en) | 2001-10-09 | 2002-10-08 | Inhibitors of the egf receptor for the treatment of thyroid cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005531488A JP2005531488A (ja) | 2005-10-20 |
| JP2005531488A5 true JP2005531488A5 (https=) | 2006-01-05 |
Family
ID=23278480
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003533940A Withdrawn JP2005531488A (ja) | 2001-10-09 | 2002-10-08 | 甲状腺癌を処置するためのｅｇｆ受容体阻害剤 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20040191254A1 (https=) |
| EP (1) | EP1435959A2 (https=) |
| JP (1) | JP2005531488A (https=) |
| AU (1) | AU2002340139A1 (https=) |
| WO (1) | WO2003030908A2 (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU9598601A (en) * | 2000-10-20 | 2002-04-29 | Eisai Co Ltd | Nitrogenous aromatic ring compounds |
| ATE508747T1 (de) * | 2003-03-10 | 2011-05-15 | Eisai R&D Man Co Ltd | C-kit kinase-hemmer |
| EP1493445A1 (en) * | 2003-07-04 | 2005-01-05 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibition of stress-induced ligand-dependent EGFR activation |
| WO2005039588A2 (en) * | 2003-10-22 | 2005-05-06 | Novartis Ag | Methods for determining the risk of developing liver and lung toxicity |
| US7683172B2 (en) * | 2003-11-11 | 2010-03-23 | Eisai R&D Management Co., Ltd. | Urea derivative and process for preparing the same |
| PE20051046A1 (es) * | 2003-11-28 | 2006-01-11 | Novartis Ag | Derivados de diaril-urea en el tratamiento de enfermedades dependientes de la quinasa de proteina |
| ATE428421T1 (de) * | 2004-09-17 | 2009-05-15 | Eisai R&D Man Co Ltd | Medizinische zusammensetzung mit verbesserter stabilität und reduzierten gelierungseigenschaften |
| WO2007015569A1 (ja) * | 2005-08-01 | 2007-02-08 | Eisai R & D Management Co., Ltd. | 血管新生阻害物質の効果を予測する方法 |
| JP4989476B2 (ja) | 2005-08-02 | 2012-08-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管新生阻害物質の効果を検定する方法 |
| AU2006309551B2 (en) | 2005-11-07 | 2012-04-19 | Eisai R & D Management Co., Ltd. | Use of combination of anti-angiogenic substance and c-kit kinase inhibitor |
| EP1964837A4 (en) * | 2005-11-22 | 2010-12-22 | Eisai R&D Man Co Ltd | Antitumor agent against multiple myeloma |
| CN104706637A (zh) * | 2006-05-18 | 2015-06-17 | 卫材R&D管理有限公司 | 针对甲状腺癌的抗肿瘤剂 |
| JPWO2008001956A1 (ja) * | 2006-06-29 | 2009-12-03 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 肝線維症治療剤 |
| WO2008026748A1 (en) * | 2006-08-28 | 2008-03-06 | Eisai R & D Management Co., Ltd. | Antitumor agent for undifferentiated gastric cancer |
| CA2676796C (en) * | 2007-01-29 | 2016-02-23 | Eisai R & D Management Co., Ltd. | Composition for treatment of undifferentiated gastric cancer |
| US8952035B2 (en) | 2007-11-09 | 2015-02-10 | Eisai R&D Management Co., Ltd. | Combination of anti-angiogenic substance and anti-tumor platinum complex |
| KR101506062B1 (ko) * | 2008-01-29 | 2015-03-25 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 혈관 저해 물질과 탁산의 병용 |
| WO2010105110A1 (en) | 2009-03-11 | 2010-09-16 | Ardea Biosciences, Inc. | Pharmaceutical combinations comprising rdea119/bay 869766 for the treatment of specific cancers |
| MY162940A (en) | 2009-08-19 | 2017-07-31 | Eisai R&D Man Co Ltd | Quinoline derivative-containing pharmaceutical composition |
| CN102958523B (zh) | 2010-06-25 | 2014-11-19 | 卫材R&D管理有限公司 | 使用具有激酶抑制作用的组合的抗肿瘤剂 |
| CN103402519B (zh) | 2011-04-18 | 2015-11-25 | 卫材R&D管理有限公司 | 肿瘤治疗剂 |
| JP6038128B2 (ja) | 2011-06-03 | 2016-12-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー |
| MY170904A (en) * | 2012-09-25 | 2019-09-13 | Chugai Pharmaceutical Co Ltd | Ret inhibitor |
| KR20150098605A (ko) | 2012-12-21 | 2015-08-28 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 퀴놀린 유도체의 비정질 형태 및 그의 제조방법 |
| NZ714049A (en) | 2013-05-14 | 2020-05-29 | Eisai R&D Man Co Ltd | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
| PT3524595T (pt) | 2014-08-28 | 2022-09-19 | Eisai R&D Man Co Ltd | Derivado de quinolina altamente puro e método para produção do mesmo |
| LT3263106T (lt) | 2015-02-25 | 2024-01-10 | Eisai R&D Management Co., Ltd. | Chinolino darinių kartumo sumažinimo būdas |
| KR102662228B1 (ko) | 2015-03-04 | 2024-05-02 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
| MX373231B (es) | 2015-06-16 | 2020-05-08 | Eisai R&D Man Co Ltd | Agente anticancerigeno. |
| US12220398B2 (en) | 2015-08-20 | 2025-02-11 | Eisai R&D Management Co., Ltd. | Tumor therapeutic agent |
| US12303505B2 (en) | 2017-02-08 | 2025-05-20 | Eisai R&D Management Co., Ltd. | Tumor-treating pharmaceutical composition |
| RU2019134940A (ru) | 2017-05-16 | 2021-06-16 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Лечение гепатоцеллюлярной карциномы |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5747598A (en) * | 1990-01-16 | 1998-05-05 | Mobil Oil Corporation | Epoxidized solid elastomeric copolymers |
| CA2082160C (en) * | 1991-03-06 | 2003-05-06 | Mary M. Bendig | Humanised and chimeric monoclonal antibodies |
| US5747498A (en) * | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| SI9620103A (sl) * | 1995-07-06 | 1998-10-31 | Novartis Ag | Pirolopirimidini in postopki za njihovo pripravo |
| US5882923A (en) * | 1996-06-27 | 1999-03-16 | Sariola; Hannu | Glial cell line-derived neurotrophic factor regulation of ureteric budding and growth |
| AU6887698A (en) * | 1997-04-08 | 1998-10-30 | Sugen, Inc. | Study and treatment of diseases related to specific cellular functions of receptor protein tyrosine kinases |
| US6987113B2 (en) * | 1997-06-11 | 2006-01-17 | Sugen, Inc. | Tyrosine kinase inhibitors |
| AR033680A1 (es) * | 2000-08-30 | 2004-01-07 | Schering Corp | Compuestos triciclicos utiles como inhibidores de la farnesil proteino transferasa y su uso para la manufactura de medicamentos como agentes antitumorales |
| GB0031080D0 (en) * | 2000-12-20 | 2001-01-31 | Novartis Ag | Organic compounds |
| GB0119249D0 (en) * | 2001-08-07 | 2001-10-03 | Novartis Ag | Organic compounds |
-
2002
- 2002-10-08 AU AU2002340139A patent/AU2002340139A1/en not_active Abandoned
- 2002-10-08 JP JP2003533940A patent/JP2005531488A/ja not_active Withdrawn
- 2002-10-08 WO PCT/US2002/032195 patent/WO2003030908A2/en not_active Ceased
- 2002-10-08 US US10/491,859 patent/US20040191254A1/en not_active Abandoned
- 2002-10-08 EP EP02778482A patent/EP1435959A2/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005531488A5 (https=) | ||
| DK1119567T3 (da) | Quinazolinderivater | |
| JP2006524660A5 (https=) | ||
| CY1106522T1 (el) | Ετepοκυκλικη ενωση και αντικαρκινικο μεσο που πepιεχει την ιδια ως δραστικο συστατικο | |
| MXPA04002338A (es) | Derivados de carbazol y su uso como antagonistas receptores del npy5. | |
| UY27384A1 (es) | Analogos de prostaglandina | |
| TW200505902A (en) | Cannabinoid receptor ligands | |
| BRPI0513843A (pt) | composto ou um sal ou solvato ou uma pró-droga farmaceuticamente aceitável do mesmo, composição farmacêutica, forma de dosagem, uso de um composto, e, sal de cloridrato | |
| RU2007116119A (ru) | Производные циклоспорина, замещенные 3-эфиром и 3-тиоэфиром, для лечения и профилактики инфекционного гепатита с | |
| NO20032510L (no) | Organiske forbindelser | |
| ZA200700765B (en) | Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of nebivolol | |
| WO2002080846A3 (en) | Epothilone derivatives and methods for making and using the same | |
| WO2001009103A3 (en) | Imidazole antiproliferative agents | |
| TW200621249A (en) | Substituted amide beta secretase inhibitors | |
| NO20064297L (no) | Aminoalkoholforbindelse | |
| NO20040881L (no) | Orale antidiabetes midler. | |
| NO20040589L (no) | Arylsulfonylderivater med 5-HT6 reseptor affinitet. | |
| NO20052074L (no) | Substituerte benzoksazinoner og anvendelser derav. | |
| EP1336407A4 (en) | MEDICAL COMPOSITIONS | |
| NO961797L (no) | Anvendelse av benzopyranderivater for fremstilling av farmasöytiske sammensetninger beregnet for behandling av patologier forbundet med den Na+-uavhengige C1-HCO3-utbytter | |
| JP2006503056A5 (https=) | ||
| UA83870C2 (ru) | Замещенные бицикло[3.1.1]гептаном производные бензимидазолона и хиназолинона как агонисты человеческих рецепторов orl1 | |
| TNSN04105A1 (en) | Imidazoquinoline derivatives | |
| NZ543068A (en) | Substituted 4-(alkyl-amide)-piperidine derivatives, processes for their preparation, and pharmaceutical compositions containing them | |
| JP2004508372A5 (https=) |